Zymeworks Inc. (ZYME)
Company Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc.
It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc.
Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
| Country | CA |
| IPO Date | Apr 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 280 |
| CEO | Kenneth H. Galbraith C.A. |
Contact Details
Address: 114 East 4th Avenue Vancouver, BC CA | |
| Website | https://www.zymeworks.com |
Stock Details
| Ticker Symbol | ZYME |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001403752 |
| CUSIP Number | 98985W102 |
| ISIN Number | US98985Y1082 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kenneth H. Galbraith C.A. | Chairman of the Board, Chief Executive Officer & President |
| Daniel Dex J.D., Ph.D. | Senior Vice President, Corporate Secretary & General Counsel |
| Diana Papove | Senior Manager of Corporate Communications |
| Dr. Jeffrey Smith M.D. | Executive Vice President & Chief Medical Officer |
| Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development |
| Dr. Paul A. Moore Ph.D. | Chief Scientific Officer |
| John Fann Ph.D. | Senior Vice President of Process Sciences |
| Laura O'Connor | Vice President of Human Resources & DEI |
| Mark Hollywood | Executive Vice President and Head of Technical & Manufacturing Operations |
| Shrinal Inamdar | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 08, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Apr 07, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Mar 27, 2025 | 4 | Filing |
| Mar 24, 2025 | 4 | Filing |
| Mar 19, 2025 | 4 | Filing |
| Mar 17, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 13, 2025 | 4 | Filing |
| Mar 05, 2025 | S-8 | Filing |
| Mar 05, 2025 | S-8 | Filing |